ArticleJournal of the Pediatric Infectious Diseases Society2026
Activity of Isavuconazole and Comparator Agents Against Pediatric Isolates From Invasive Fungal Infections.
Article in Journal of the Pediatric Infectious Diseases Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundInvasive fungal infections (IFIs) are a rising problem among pediatric patients. Antifungal agents have data supporting treatment in pediatric patients of varying ages and infection types but in vitro susceptibility data for large collections of pediatric isolates are lacking, which limits empiric treatment. We describe in vitro antifungal susceptibility testing of 900 contemporary yeast and mold isolates collected from IFIs in patients ≤ 17 years of age as a part of the SENTRY Antifungal Surveillance Program.
methodsA total of 900 isolates (743 yeasts and 157 molds) were collected from 28 countries between 2017 and 2024. Antifungal susceptibility testing was performed by broth microdilution according to Clinical and Laboratory and Standards Institute (CLSI) methodology.
resultsA total of 33.4% of isolates were from patients ≤ 1 year old, 22.1% from patients aged 2-5 years old, 24.4% from patients aged 6-12 years old, and 20.0% from patients aged 13-17 years old. In total, 63.0% of yeasts were recovered from patients ≤ 5 years old; 79.6% of molds were from patients ≥ 6 years old. Most yeast isolates (72.5%) were from bloodstream infections; most mold isolates (61.8%) were from the respiratory tract. By CLSI breakpoints, 88.5% and 87.5% of Aspergillus fumigatus isolates were susceptible to voriconazole and isavuconazole, respectively. Against Mucorales, the isavuconazole minimum inhibitory concentration (MIC)50 value was 4 mg/L, whereas the MIC50 values for voriconazole and posaconazole were > 8 mg/L. All agents had low MICs against most yeasts collected and there were few resistant or non-wildtype yeasts.
conclusionsBroth microdilution among a diverse collection of isolates obtained from IFIs among pediatric patients showed low rates of resistance to echinocandins or azoles. Across species, the lowest MICs were observed for voriconazole and isavuconazole in yeasts. All triazoles were highly active against Aspergillus spp. Against non-Aspergillus molds, isavuconazole, posaconazole, and amphotericin B were the most active agents. These data can guide the antifungal treatment of IFIs in pediatric patients when susceptibility testing is unavailable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.